小剂量艾司氯胺酮对老年患者关节置换术后睡眠障碍的临床观察研究

注册号:

Registration number:

ChiCTR2500104624 

最近更新日期:

Date of Last Refreshed on:

2025-06-19 16:41:31 

注册时间:

Date of Registration:

2025-06-19 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

小剂量艾司氯胺酮对老年患者关节置换术后睡眠障碍的临床观察研究

Public title:

Clinical observation and study of low-dose esketamine on sleep disorders in elderly patients after joint replacement surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

小剂量艾司氯胺酮对老年患者关节置换术后睡眠障碍的临床观察研究

Scientific title:

Clinical observation and study of low-dose esketamine on sleep disorders in elderly patients after joint replacement surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

韦晨浦 

研究负责人:

韦晨浦 

Applicant:

Chenpu Wei 

Study leader:

Chenpu Wei 

申请注册联系人电话:

Applicant telephone:

+86 136 0245 0857

研究负责人电话:

Study leader's
telephone:

+86 136 0245 0857

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

weichenpu_0@126.com

研究负责人电子邮件:

Study leader's E-mail:

weichenpu_0@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东广州市越秀区大通路261号

研究负责人通讯地址:

广东广州市越秀区大通路261号

Applicant address:

No. 261, Datong Road, Yuexiu District, Guangzhou City, Guangdong

Study leader's address:

261 datong Road , yuexiu District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院二沙分院

Applicant's institution:

Ersha Island Branch of Guangdong Hospital of Traditional Chinese Medicine

研究负责人所在单位:

广东省中医院二沙分院

Affiliation of the Leader:

Ersha Island Branch of Guangdong Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

ZF-2024-265-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2024-08-19 00:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广州市越秀区大德路111号科研大楼1912室

Contact Address of the ethic committee:

Room 1912, Research Building, 111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8188 7233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州中医药大学第二附属医院(广东省中医院二沙分院)

Primary sponsor:

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine(Ersha Island Branch of Guangdong Hospital of Traditional Chinese Medicine)

研究实施负责(组长)单位地址:

广东广州市越秀区大通路261号

Primary sponsor's address:

261 datong Road , yuexiu District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院二沙分院

具体地址:

广东广州市越秀区大通路261号

Institution
hospital:

Ersha Island Branch of Guangdong Hospital of Traditional Chinese Medicine)

Address:

261 datong Road , yuexiu District, Guangzhou, Guangdong, China

经费或物资来源:

自筹经费

Source(s) of funding:

self-financing

研究疾病:

老年人睡眠障碍  

Target disease:

Sleep disorders in elderly people

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索小剂量艾司氯胺酮对老年患者关节置换手术术后睡眠障碍的临床观察,从而增加患者术后舒适度,以便患者更好的快速康复  

Objectives of Study:

Exploring the clinical observation of low-dose esketamine on sleep disorders in elderly patients after joint replacement surgery, in order to increase postoperative comfort and facilitate faster recovery

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.体重指数高于30; 2.术前匹兹堡睡眠质量指数(PSQI)高于7; 3.对艾司氯胺酮过敏或有艾司氯胺酮禁忌症患者; 4.认知功能障碍或无法沟通。

Exclusion criteria:

1. Body mass index higher than 30; 2. Preoperative Pittsburgh Sleep Quality Index (PSQI) higher than 7; 3. Patients who are allergic to esketamine or have contraindications to esketamine; 4. Cognitive dysfunction or inability to communicate.

研究实施时间:

Study execute time:

From 2024-08-19 00:00:00 To 2025-12-19 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-19 00:00:00 To 2025-12-19 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

60

Group:

Test group

Sample size:

干预措施:

麻醉诱导前艾司氯胺酮0.25mg/kg,术中持续泵注,注射速度0.3mg/kg/h

干预措施代码:

Intervention:

Before anesthesia induction,esketamine 0.25mg/kg was administered continuously by pump during surgery at an injection rate of 0.3mg/kg/h

Intervention code:

组别:

对照组

样本量:

60

Group:

Control group

Sample size:

干预措施:

不使用艾司氯胺酮,正常麻醉

干预措施代码:

Intervention:

No use of esketamine, normal anesthesia

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China

Province:

Guangdong

City:

单位(医院):

广东省中医院二沙分院 

单位级别:

三级甲等 

Institution
hospital:

Ersha Island Branch of Guangdong Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

安森斯量表评分

指标类型:

主要指标

Outcome:

Anson Douleur de l’Accouchement Scale Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

主要指标

Outcome:

Numeric Rating Scale, NRS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数

指标类型:

次要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑和抑郁评分

指标类型:

次要指标

Outcome:

Anxiety and depression scores

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者之一先按病例纳入顺序将患者编号1-120。查随机数字表产生120个随机数,将随机数从小到大排列后得到序号R,并规定R=1~60者为试验组组,R=61~120者为对照组组

Randomization Procedure (please state who generates the random number sequence and by what method):

One of the researchers number the patients 1-120 according to case inclusion order. Look up the table of Random Numbers to generate 120 random numbers, arrange the random numbers from small to large named number R, specify that R=1-60 isTest group , R=61-120 is control group .

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

none

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

预计于2025年12月在www.medresman.org.cn共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

It is expected to be shared in www.medresman.org.cn in December 2025

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-06-19 16:41:21